AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8497681
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation 10 min before sBPT (treatment A)
Trial: 8497681
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation 2 h before sBPT (treatment B)
Trial: 3518726
Drug: Ibopamine in
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine in association with digitalis and diuretics (10 patients, Group 1)
Trial: 3518726
Drug: Digitalis and
RxNorm normalized name: Digitalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitalis and diuretics (8 patients, Group 2)
Trial: 29406465
Drug: Daptomycin (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (7 mg/kg for 12-17 years, 9 mg/kg for 7-11 years, 12 mg/kg for 1-6 years)
Trial: 27124034
Drug: Deep group
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep group (LMA removed under deep anesthesia with propofol at 2 μg/mL)
Trial: 22276745
Drug: Immediate salvage
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate salvage therapy (no-ARDFP group)
Trial: 22276745
Drug: ARV drug-free
RxNorm normalized name: Arv-110 (protac)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARV drug-free period (ARDFP)
Trial: 19625976
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) ingestion at a dosage of 0.3 g.kg(‐1) body weight (BW)
Trial: 19625976
Drug: NaCl placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl placebo (PLAC) at a dosage of 0.045 g.kg(‐1) BW
Trial: 14991337
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A treatment
Trial: 19050545
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A combined with other treatment modalities
Trial: 19050545
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A treatment across multiple facial areas
Trial: 15857066
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (bioabsorbable membranes with a bone replacement graft)
Trial: 10440429
Drug: Aspirin (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (active control)
Trial: 2014712
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nicergoline once daily
Trial: 2014712
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg co-dergocrine mesilate once daily
Trial: 31856887
Drug: Twice-daily nebulised
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily nebulised hypertonic saline (HTS 6%)
Trial: 31856887
Drug: Carbocisteine (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day)
Trial: 31856887
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of twice-daily nebulised HTS and carbocisteine
Trial: 17631079
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm control (attempting to maintain sinus rhythm, principally with antiarrhythmic drugs)
Trial: 11057794
Drug: Meropenem (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (500 mg) administered intravenously every 12 hrs
Trial: 9493076
Drug: High-dose growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose growth hormone (GH) treatment, daily s.c. dose of either 0.2 or 0.3 IU/kg for 2 years
Trial: 9493076
Drug: High-dose growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose growth hormone (GH) treatment
Trial: 3531567
Drug: Ceftizoxime suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime suppository (CZX‐S), 250 mg, four times daily for 7 days
Trial: 3531567
Drug: Ceftizoxime intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime intravenous injection (CZX), 60 mg/kg body weight, four times daily for 7 days
Trial: 3531567
Drug: Ceftizoxime suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime suppository (CZX‐S)
Trial: 3531567
Drug: Ceftizoxime intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime intravenous injection (CZX)
Trial: 30289435
Drug: MK-2048 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2048 (30 mg) and vicriviroc (VCV, 182 mg) vaginal rings used continuously for 28 days
Trial: 30022409
Drug: Patient-family agenda
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-family agenda setting intervention (self-administered paper-pencil checklist)
Trial: 26184078
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg melatonin
Trial: 22348831
Drug: 0.4% L-menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% L-menthol (n = 32)
Trial: 22348831
Drug: 0.8% L-menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8% L-menthol (n = 35)
Trial: 22348831
Drug: 1.6% L-menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6% L-menthol (n = 30)
Trial: 45587
Drug: Dihydrocodeine 60
RxNorm normalized name: dihydrocodeine bitartrate 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocodeine 60 mg
Trial: 9473085
Drug: Nucleus 22
RxNorm normalized name: SUS SCROFA THALAMUS LATERAL GENICULATE NUCLEUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleus 22 and Med-El Combi 40 cochlear implants
Trial: 2474103
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dietary sodium restriction and ACE inhibitors
Trial: 2474103
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of a thiazide diuretic
Trial: 320712
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with factor VIII or factor IX concentrate and a reducing dose of prednisolone
Trial: 26333778
Drug: Standard antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antimicrobial therapy plus daily granulocyte transfusions from donors stimulated with G-CSF and dexamethasone
Trial: 26333778
Drug: Standard antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antimicrobial therapy
Trial: 21608218
Drug: Conventional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapies (Control group)
Trial: 15083284
Drug: Natalizumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab (3 mg/kg or 6 mg/kg)
Trial: 7948819
Drug: Branched-chain amino
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain amino acid solution (Aminoleban), intravenous infusion for 3 hours
Trial: 29274894
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of telephone counseling with the internet-based walking program
Trial: 27528177
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg 3 times daily for 2 weeks
Trial: 27528177
Drug: Placebo 3
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 times daily for 2 weeks
Trial: 19108789
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (T4 Montpellier 100)
Trial: 19108789
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Synthroid)
Trial: 19108789
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (T4 Montpellier 100) with baseline adjustment
Trial: 19108789
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Synthroid) with baseline adjustment
Trial: 15996609
Drug: Heat wrap
RxNorm normalized name: Softheat Ultra Back Heat Wrap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat wrap therapy alone (n=25)
Trial: 15996609
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of heat wrap therapy and exercise (heat+exercise, n=24)
Trial: 8694321
Drug: Amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 25 mg daily
Trial: 26051022
Drug: Telephone-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based cognitive-behavioral therapy (CBT) intervention
Trial: 23515142
Drug: Tocilizumab 8
RxNorm normalized name: tocilizumab 80 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 8 mg per kg bodyweight intravenously every 4 weeks plus placebo subcutaneously every 2 weeks
Trial: 23515142
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg subcutaneously every 2 weeks plus placebo intravenously every 4 weeks
Trial: 10350034
Drug: Buspirone (20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (20-60 mg/day, mean daily dose 48.5 mg)
Trial: 8606118
Drug: Bivalent vaccine
RxNorm normalized name: PAPILLOMAVIRUS BIVALENT VACCINE INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent vaccine composed of Vibrio cholerae CVD 103‐HgR and Salmonella typhi Ty21a
Trial: 1954640
Drug: 0.025% capsaicin
RxNorm normalized name: CAPSAICIN 2.5 mg in 10 g TOPICAL PATCH [0.025% Capsaicin Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% capsaicin cream applied four times daily for four weeks
Trial: 7318332
Drug: Dihydralazine (16.2‐32.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine (16.2‐32.4 mg/2 h) plus saline
Trial: 7318332
Drug: Dihydralazine (16.2‐32.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine (16.2‐32.4 mg/2 h) plus diclofenac (75 mg/20 ml saline)
Trial: 6499689
Drug: Meclozine tablets
RxNorm normalized name: meclozine
DrugBank: Meclizine (DB00737)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meclozine tablets
Trial: 24377410
Drug: modified cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified cognitive behavioral therapy (m-CBT)
Trial: 24377410
Drug: usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: usual care (UC) therapy
Trial: 19533356
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg by mouth every morning)
Trial: 19533356
Drug: Aerosolized, swallowed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized, swallowed fluticasone (440 mcg by mouth twice a day)
Trial: 12599218
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy for Stage II breast carcinoma
Trial: 19496252
Drug: Inhaled methacholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methacholine
Trial: 7109137
Drug: Individualized method
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized method for calculating gentamicin dosage
Trial: 31238081
Drug: Soy beverage
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy beverage (200 ml consumed once a day for 15 days)
Trial: 31238081
Drug: Bovine milk
RxNorm normalized name: Bovine Milk Plasma
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine milk (200 ml consumed once a day for 15 days)
Trial: 21719715
Drug: Combined clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined clinic (CC)
Trial: 20649426
Drug: Acyclovir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (400 mg, twice daily)
Trial: 18041171
Drug: Grazax (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazax (oral vaccine)
Trial: 9917081
Drug: Tramadol titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol titrated at 10 days to achieve 200 mg/day
Trial: 9917081
Drug: Tramadol titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol titrated at 4 days to achieve 200 mg/day
Trial: 9917081
Drug: Tramadol titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol titrated at 1 day to achieve 200 mg/day
Trial: 1962781
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy and thoracic irradiation
Trial: 7282733
Drug: Oral aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aminophylline (0.4 to 0.6 g)
Trial: 7282733
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both (aminophylline and metaproterenol)
Trial: 8239103
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg methylprednisolone acetate suspension
Trial: 25972203
Drug: CrossFit Teens™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CrossFit Teens™ resistance training programme (60 min, twice per week for 8 weeks)
Trial: 25939638
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (0.1 mg/kg body weight) and nitrous oxide‐oxygen sedation
Trial: 25939638
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.2 mg/kg body weight) and nitrous oxide‐oxygen sedation
Trial: 16421476
Drug: Carvedilol 12.5-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 12.5-25 mg
Trial: 11545670
Drug: General medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General medicine clinic (n = 61)
Trial: 9259053
Drug: Aminophylline (nonspecific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (nonspecific competitive adenosine receptor antagonist)
Trial: 2573572
Drug: Somatostatin (250-micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (250-micrograms bolus and 250-micrograms per hr infusion, with repeat bolus and doubling of the infusion if bleeding was not controlled)
Trial: 1026339
Drug: Intensive-chemotherapy schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive-chemotherapy schedule
Trial: 19889003
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy alone
Trial: 20521030
Drug: Baclofen (60,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (60, 90 mg/day) for 16 days
Trial: 20521030
Drug: Mirtazapine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (30 mg/day) for 14 days
Trial: 16002558
Drug: Cimetidine (2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (2.3 mg/min over 50 min)
Trial: 31036625
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg every 6 months (Q6M)
Trial: 31036625
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg every 3 months (Q3M)
Trial: 20446755
Drug: Leukotriene receptor
RxNorm normalized name: Leukotriene receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene receptor antagonists (LTRAs)
Trial: 15673691
Drug: MCI-196 6
RxNorm normalized name: kaolin 196 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCI-196 6 g/day
Trial: 12627359
Drug: Oral valacyclovir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir, 2 g q.i.d.
Trial: 12627359
Drug: Intravenous ganciclovir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week
Trial: 27492941
Drug: Cardiac rehabilitation
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac rehabilitation (12 weeks of physical exercise and monthly psycho-educational consultations)
Trial: 18678160
Drug: Blood-letting puncture
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood-letting puncture plus red-hot needle therapy
Trial: 16450688
Drug: Tramadol 37.5
RxNorm normalized name: ACETAMINOPHEN 325MG/TRAMADOL 37.5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 37.5 mg/APAP 325 mg (mean, 4.3 tablets)
Trial: 16450688
Drug: Codeine 30
RxNorm normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine 30 mg/APAP 300 mg (mean, 4.6 tablets)
Trial: 12891252
Drug: G‐CSF (filgrastim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (filgrastim) 5 mg/kg/day
Trial: 1678735
Drug: Metadoxine 900
RxNorm normalized name: metadoxine
DrugBank: Metadoxine (DB16554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metadoxine 900 mg twice daily eluted in 500 ml of saline infusion
Trial: 1678735
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: 500 ml of saline infusion twice daily with equivalent doses of pyridoxine (40 mg/die) every morning
Trial: 29698106
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of MS-Contin (morphine)
Trial: 30758402
Drug: Iodoform paste
RxNorm normalized name: Iodoform
DrugBank: Iodoform (DB13813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodoform paste (iodoform + camphorated parachlorophenol + ointment comprising prednisolone acetate 5.0 mg and rifamycin 1.5 mg)
Trial: 29046518
Drug: Oxycodone (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (0.05 mg/kg)
Trial: 18418361
Drug: Memantine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (40 mg)
Trial: 17314582
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of ultracain
Trial: 11196267
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) 5.0 microg/kg per day
Trial: 11196267
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) 10.0 microg/kg per day
Trial: 9281302
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine daily
Trial: 8052927
Drug: Pulse methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulse methylprednisolone (400 mg/day)
Trial: 8052927
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (50 mg/day)
Trial: 2720577
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg MS Contin tablet
Trial: 2720577
Drug: Three 30
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 30 mg MS Contin tablets
Trial: 31154571
Drug: 30-mg zinc
RxNorm normalized name: zinc citrate 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-mg zinc gluconate for 12 weeks
Trial: 25968598
Drug: Sulforaphane (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulforaphane (60 mg daily for 6 months)
Trial: 19085178
Drug: Trans-dermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trans-dermal fentanyl (TDF) patch (Group F, n=25)
Trial: 19085178
Drug: Sustained-release oral
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release oral morphine (SRM) (Group M, n=25)
Trial: 19085178
Drug: Trans-dermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trans-dermal fentanyl (TDF) patch (Group F)
Trial: 19085178
Drug: Sustained-release oral
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release oral morphine (SRM) (Group M)
Trial: 29659193
Drug: Orlistat 27-mg
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 27-mg chewable tablet
Trial: 30021690
Drug: Orlistat 60-mg
RxNorm normalized name: orlistat 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 60-mg capsule